aTyr Pharma, Inc.

Contributing Author

Recent Articles by aTyr Pharma, Inc.

Sep-30	aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025 ATYR GlobeNewswire
Sep-15	aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis ATYR GlobeNewswire
Sep-05	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ATYR GlobeNewswire
Aug-07	aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update ATYR GlobeNewswire
Jul-22	aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT Study of Efzofitimod in Patients with Pulmonary Sarcoidosis ATYR GlobeNewswire
Jun-26	aTyr Pharma to be Added to the Russell 2000 and Russell 3000 Indexes ATYR GlobeNewswire
Jun-04	aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) ATYR GlobeNewswire
May-20	aTyr Pharma to Present at Upcoming Investor Conferences ATYR GlobeNewswire
May-19	aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference ATYR GlobeNewswire
May-16	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ATYR GlobeNewswire
May-14	aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis ATYR GlobeNewswire
May-07	aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update ATYR GlobeNewswire